2023-05-02 16:12:00 ET
- Dynavax press release ( NASDAQ: DVAX ): Q1 GAAP EPS of -$0.19 misses by $0.06 .
- Revenue of $46.92M (-58.8% Y/Y) beats by $8.33M .
-
Full year 2023 financial guidance is reiterated and consists of the following expectations:
- HEPLISAV-B net product revenue between approximately $165 - $185 million
- Research and development expenses between approximately $55 - $70 million
- Selling, general and administrative expenses between approximately $135 - $155 million
For further details see:
Dynavax GAAP EPS of -$0.19 misses by $0.06, revenue of $46.92M beats by $8.33M